Isentress

E468958

Isentress is an antiretroviral medication (an HIV integrase inhibitor) used to treat HIV infection in adults and children.

Try in SPARQL Jump to: Surface forms Statements Referenced by

Observed surface forms (1)

Surface form Occurrences
Isentress HD 0

Statements (47)

Predicate Object
instanceOf HIV integrase inhibitor
antiretroviral medication
brand name drug
high-dose formulation of Isentress
alsoKnownAs raltegravir NERFINISHED
approvalYear 2007
approvedBy U.S. Food and Drug Administration NERFINISHED
ATCCode J05AX08
canCauseAdverseEffect depression
elevated liver enzymes
fatigue
headache
insomnia
nausea
rash
suicidal ideation
developedBy Merck & Co. NERFINISHED
dosageForm chewable tablet
film-coated tablet
oral suspension
tablet
eliminationRoute feces
urine
hasActiveIngredient raltegravir NERFINISHED
hasBlackBoxWarning no
hasBrandOwner Merck Sharp & Dohme Corp. NERFINISHED
hasContraindication known hypersensitivity to raltegravir
hasDrugClass integrase strand transfer inhibitor
hasHalfLife approximately 9 hours
indicatedFor treatment-experienced HIV patients
treatment-naive HIV patients
use in combination with other antiretroviral agents
isAvailableAs Isentress HD NERFINISHED
isFirstInClass yes
isPartOfTherapy combination antiretroviral therapy
legalStatusEU prescription only
legalStatusUS prescription only
mechanismOfAction inhibits HIV integrase enzyme
prevents integration of viral DNA into host genome
metabolism primarily by UGT1A1-mediated glucuronidation
pregnancyCategoryUS C
routeOfAdministration oral
target HIV-1 integrase NERFINISHED
treats HIV infection
HIV-1 infection
usedIn adult patients
pediatric patients

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

Merck & Co. notableDrug Isentress